B
CBAY

Bailard’s Cymabay Therapeutics CBAY Stock Holding History

Bailard’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-13,700
Closed -$46K – 820
2021
Q4 		$46K Buy
+13,700
New +$52K ﹤0.01% 712
2019
Q4 		– Sell
-308,700
Closed -$1.58M – 620
2019
Q3 		$1.58M Hold
308,700
– – 0.1% 177
2019
Q2 		$2.21M Buy
308,700
+93,600
+44% +$1.06M 0.14% 148
2019
Q1 		$2.86M Buy
215,100
+90,100
+72% +$958K 0.18% 120
2018
Q4 		$984K Buy
+125,000
New +$1.19M 0.07% 218

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

Bailard's CBAY Position: Q1 2022 in Review

Bailard sold out of Cymabay Therapeutics (CBAY) in Q1 2022, closing a stake of 13,700 shares — an estimated $46K sold.

Bailard first reported a position in CBAY in Q4 2018 and held it in 5 quarters. The position peaked at $2.86M in Q1 2019. 118 funds tracked by Wall St. Rank hold CBAY as of Q1 2022.

  • Bailard reported no remaining Cymabay Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Bailard sold 13,700 Cymabay Therapeutics shares in Q1 2022, an estimated $46K.
  • Bailard first reported a position in Cymabay Therapeutics in Q4 2018 and held it in 5 quarters.
  • Bailard's Cymabay Therapeutics position peaked at $2.86M in Q1 2019.
  • 118 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2022.

Based on Bailard's 13F filing for Q1 2022, filed 25 Apr 2022.